WISPer Trial: Investigational New Treatment for IPF

Trial Objectives

---

Idiopathic pulmonary fibrosis, or IPF, is a rare lung disease that causes scarring, or fibrosis, in the lungs, leading to difficulty breathing and other chronic symptoms. Researchers are evaluating a new medication, called MTX-463, to determine if it can safely and effectively reduce IPF symptoms over time.

Volunteers in this study will be randomly assigned to receive either the study medication or a placebo (a medication containing no active ingredient) as an infusion. At clinic visits, volunteers will complete questionnaires about their symptoms, receive physical exams and lung function tests, and provide blood samples. The data collected will help researchers determine if this new medication helps improve lung function over time.